PMID- 38011404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231129
IS  - 2717-011X (Electronic)
IS  - 2717-011X (Linking)
VI  - 19
IP  - 3
DP  - 2020 Jul 5
TI  - The efficacy and safety of oral disease-modifying therapies for 
      relapsing-remitting multiple sclerosis: A systematic review.
PG  - 138-145
LID - 10.18502/cjn.v19i3.5427 [doi]
AB  - Background: Although widely used, first-line injectable medicines for the 
      treatment of multiple sclerosis (MS) remain an issue of efficacy and adherence. 
      Recently, new oral medications for MS have contributed to dramatic improvements 
      in MS treatment. This study aims to evaluate the safety and efficacy of oral 
      disease-modifying drugs (DMDs) used in relapsing-remitting MS (RRMS). Methods: A 
      systematic review was conducted on related databases including PubMed, Scopus, 
      Cochrane, and Web of Science up to April 2020. The screening of the studies and 
      their quality assessment was carried out independently by the two authors. 
      Results: Three studies fulfilled the predefined criteria of inclusion. One of 
      them compared teriflonomide with subcutaneous interferon beta-1a (IFN beta-1a), 
      another compared oral fingolimod with intramuscular (IM) IFN beta-1b, and the third 
      article compared oral fingolimod with IM IFN beta-1a. No eligible study was found 
      for dimethyl fumarate (DMF). The results indicated that while the efficacy of 
      fingolimod was more than IFN beta (IM beta-1a and beta-1b), teriflunomide 7 mg had less 
      efficacy than subcutaneous IFN beta-1a. Regarding safety, the results indicated that 
      the proportion of diabetic patients with adverse events (AEs) in the fingolimod 
      group was higher than in the IFN beta-1b group and the overall occurrence of AEs was 
      similar between teriflunomide and IFN beta-1a groups. Conclusion: There is evidence 
      for the effectiveness of fingolimod in reducing annualized relapse rates (ARRs) 
      and improving magnetic resonance imaging (MRI) findings, but the evidence does 
      not support the effectiveness of teriflunomide and further studies are required 
      to determine its efficacy. Also, fingolimod is associated with more side effects 
      than IFN beta-1b, but there is no evidence to suggest any difference in side effects 
      between teriflunomide and IFN beta-1a.
CI  - Copyright (c) 2020 Iranian Neurological Association, and Tehran University of 
      Medical Sciences. Published by Tehran University of Medical Sciences.
FAU - Shahtaheri, Rahil Sadat
AU  - Shahtaheri RS
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Nikfar, Shekoufeh
AU  - Nikfar S
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Pharmaceutical Management and Economics Research Center, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Khorasani, Elahe
AU  - Khorasani E
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sabbagh-Baniazad, Mansoureh
AU  - Sabbagh-Baniazad M
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Goudarzi, Zahra
AU  - Goudarzi Z
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of 
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Emamikhah, Maziar
AU  - Emamikhah M
AD  - Department of Neurology, Rasool-e Akram Hospital, Iran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Curr J Neurol
JT  - Current journal of neurology
JID - 101769679
PMC - PMC8185589
OTO - NOTNLM
OT  - Disease-Modifying Therapy
OT  - Multiple Sclerosis
OT  - Systematic Review
EDAT- 2020/07/05 00:00
MHDA- 2020/07/05 00:01
PMCR- 2020/07/05
CRDT- 2023/11/27 14:56
PHST- 2020/03/16 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/07/05 00:01 [medline]
PHST- 2020/07/05 00:00 [pubmed]
PHST- 2023/11/27 14:56 [entrez]
PHST- 2020/07/05 00:00 [pmc-release]
AID - CJN-19-138 [pii]
AID - 10.18502/cjn.v19i3.5427 [doi]
PST - ppublish
SO  - Curr J Neurol. 2020 Jul 5;19(3):138-145. doi: 10.18502/cjn.v19i3.5427.